INTERESTED IN THIS RESEARCH?
Contact our analysts for inquiries, samples, and expert insights.
REPORT OUTLOOK
| Market Size | CAGR | Dominating Region |
|---|---|---|
| USD 44.22 billion | 11.3% | North America |
| By Product | By Application | By End Use |
|---|---|---|
|
|
|
SCOPE OF THE REPORT
Cancer Diagnostics Market Overview
Cancer diagnostics market size was valued at USD 16.87 billion in 2020 and is projected to reach USD 44.22 billion by 2029, growing at a CAGR of 11.3% from 2022 to 2029.
Current cancer diagnosis and therapy methods have serious flaws. Since a decade ago, novel nano-platforms providing simultaneous diagnostic and therapeutic functions for cancer, dubbed theranostic agents or simply theranostics, have emerged as a result of increasing knowledge and technological advancement in cancer biology, material science, and particularly nanomedicine. These innovative nanodevices can target several cancer markers and kill cancer cells in a synergetic manner, overcoming cancer heterogeneity and adaptive resistance difficulties. Furthermore, theranostics cancer medicines can be directed by diagnostic imaging results, resulting in improved cancer treatment. Ideal theranostics should have a compact size and surface chemistry for efficient cellular absorption, ultrasensitive imaging of many tumour-specific markers, desirable cancer targeting ability, and high loading and controlled release of anticancer medicines, in particular designs. Other cancer medications, in addition to chemotherapy, are required in most designs. Advances in material science and engineering, notably the production of nanocomposites, are required to meet these multifunctional needs for theranostics.
Advances in cancer diagnoses and therapy have resulted in a large increase in survival rates, particularly among children with cancer, resulting in a paradigm change in attention toward long-term survivorship and quality-of-life issues. While cardiac, pulmonary, renal, and hepatic functions are routinely evaluated prior to, during, and after treatment, the reproductive system is not. As more girls and women survive cancer, it’s more important than ever to predict the effects of cancer and its treatment on the ovary and provide options to protect this population’s reproductive and sexual function in the future.
| ATTRIBUTE | DETAILS |
| Study period | 2020-2029 |
| Base year | 2021 |
| Estimated year | 2022 |
| Forecasted year | 2022-2029 |
| Historical period | 2018-2020 |
| Unit | Value (USD Billion) |
| Segmentation | By Product, By Application, By End Use, Region
|
| By Product |
|
| By Application |
|
| By End Use |
|
| By Region |
|
The cancer diagnostics market would grow due to an increase in the incidence and prevalence of various types of cancer, such as breast cancer and lung cancer, over the forecast period. Furthermore, during the projection period, the cancer diagnostics sector will benefit from a surge in technical breakthroughs that aid in improved imaging of cancerous cells, improvements in equipment to detect the kind of cancer, and an increase in the efficiency of the results. Increased government activities and other private organisations aimed at raising awareness about early cancer detection and prevention are expected to drive market expansion in the future years. Furthermore, in the coming years, the market is likely to be driven by an increase in the number of diagnostics laboratories in developed countries. During the forecast period, a sharp increase in emphasis on health and safety laws, as well as a surge in popularity of yoga and other health-related practises, will provide a growth opportunity.
Government rules, a nationwide lockdown, and a spike in infection rates across countries all had a significant financial impact on neurology hospitals and clinics. Several hospitals and clinics have seen a decrease in patient visits as a result of COVID-19, resulting in reduced client engagement. Furthermore, the COVID-19 situation has caused numerous cancer tests to be delayed. There is a scarcity of medical care for disorders other than COVID-19 around the world, which has had a negative impact on the cancer diagnostics business. At the same time, limited healthcare staff availability around the world is another aspect that has a negative impact on the cancer diagnostics market.
Increased understanding of certain cancer biomarkers is creating a huge commercial opportunity for treating cancer patients through improving detection. The identification of prospective cancer biomarkers has been made possible by technological advances in the field of biotechnology, and some of these biomarkers have been marketed.
However, rising capital investments and low benefit-cost ratio for biomarkers, rising helium shortages, and rising risk of high radiation exposure likely to limit the use of CT scanners are among the major factors obstructing market growth, while rising stringent regulatory guidelines and rising adoption of refurbished diagnostic imaging systems will further challenge the market growth in the forecast period. Due to increased costs, lower reimbursement rates, and budgetary constraints, many hospitals in poorer nations are unable to invest in diagnostic imaging technology. However, because of the increasing demand for diagnostic imaging operations in these countries, hospitals that cannot afford to purchase new imaging equipment choose to use second-hand systems. Refurbished systems are less expensive than new systems, costing between 40% and 60% of the original purchase price.
Cancer Diagnostics Market Segment Analysis
On the basis of product, the consumables segment is the major revenue contributor, and is projected to grow significantly during the forecast period. Increased adoption of consumables for cancer diagnostics, an increase in cancer prevalence, an increase in R&D investment, an increase in the geriatric population, the introduction of technologically advanced products, and an increase in the launch of new & advanced kits and reagents are all driving the segment’s growth.
Due to the rise in breast cancer occurrence around the world and an increase in the population of women aged 50 to 74, the breast cancer segment is the largest stakeholder in the cancer diagnostics market, depending on application. In the next years, an increase in the number of efforts conducted by various groups will help the industry gain traction.
The hospitals & clinics segment, based on end use, is the largest shareholder in the cancer diagnostics market, owing to an increase in the number of patients visiting hospitals, an increase in the number of in-house diagnostic procedures performed in hospitals, and an increase in awareness about early diagnosis, all of which are major driving factors for this market.
Cancer Diagnostics Market Players
The major players covered in the cancer diagnostics market report are Abbott, Agilent Technologies, Inc., BD, BioMérieux SA, NeoGenomics Laboratories, Inc., Telerad Tech, F. Hoffmann-La Roche Ltd, GENERAL ELECTRIC COMPANY, Hologic Inc., Illumina, Inc., QIAGEN, BioGenex, Siemens Healthcare GmbH, BioNTech Diagnostics GmbH, Thermo Fisher Scientific Inc. and Koninklijke Philips N.V. among other domestic and global players.
- Abbott is a globally diversified healthcare company with a central purpose to help people live their healthiest possible lives. We offer a broad portfolio of market-leading products that align with favourable long-term healthcare trends in both developed and developing markets.
- Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California. Agilent was established in 1999 as a spin-off from Hewlett-Packard.
- NeoGenomics is a premier cancer diagnostic, pharma services, and information services company serving oncologists, pathologists, pharmaceutical companies, and academic centres in their pursuit of providing better futures for people living with cancer.
Who Should Buy? Or Key Stakeholders
- Healthcare Industry
- Hospitals and Clinics
- Medical Laboratories
- Pharmaceutical Industry
- Scientific Research and Development
- Investors
- Manufacturing companies
- End user companies
- Others
Cancer Diagnostics Market Regional Analysis
The global cancer diagnostics market by region includes North America, Asia-Pacific (APAC), Europe, South America, and Middle East & Africa (MEA).
- North America: includes the US, Canada, Mexico
- Asia Pacific: includes China, Japan, South Korea, India, Australia, ASEAN and Rest of APAC
- Europe: includes UK, Germany, France, Italy, Spain, Russia, and Rest of Europe
- South America: includes Brazil, Argentina and Rest of South America
- Middle East & Africa: includes Turkey, UAE, Saudi Arabia, South Africa, and Rest of MEA
North America is predicted to play a significant role in the growth of the cancer diagnostics industry. The emergence of COVID-19 had a negative impact on the market examined in the region. According to the Union for International Cancer Controls (UICC), cancer diagnosis rates in the United States dropped significantly during the epidemic. According to the survey’s findings, the number of newly diagnosed metastatic non-small cell lung cancer patients decreased by just over 30% from February to March 2020. Colorectal cancer (14 percent), acute myeloid leukaemia (14 percent), breast cancer (8.4%), and ovarian cancer (14 percent) also saw declines (8.6 percent). Such occurrences point to a decrease in cancer diagnosis rates during the pandemic era.
Key Market Segments: Cancer Diagnostics Market
Cancer Diagnostics Market By Product, 2020-2029, (USD Million)
- Consumables
- Instruments
Cancer Diagnostics Market By Application, 2020-2029, (USD Million)
- Breast Cancer
- Lung Cancer
- Blood Cancer
- Colorectal Cancer
- Skin Cancer
- Ovarian Cancer
- Prostate Cancer
- Kidney Cancer
- Liver Cancer
- Pancreatic Cancer
- Cervical Cancer
Cancer Diagnostics Market By End Use, 2020-2029, (USD Million)
- Hospitals & Clinics
- Diagnostic Laboratories
- Diagnostic Centres
- Research Institutes
Cancer Diagnostics Market By Region, 2020-2029, (USD Million)
- North America
- Europe
- Asia Pacific
- South America
- Middle East and Africa
Important Countries In All Regions Are Covered.
Key Question Answered
- What are the growth opportunities related to the adoption of cancer diagnostics across major regions in the future?
- What are the new trends and advancements in the cancer diagnostics market?
- Which product categories are expected to have highest growth rate in the cancer diagnostics market?
- Which are the key factors driving the cancer diagnostics market?
- What will the market growth rate, growth momentum or acceleration the market carries during the forecast period?
Table of Content
- Introduction
- Market Definition
- Market Segmentation
- Research Timelines
- Assumptions and Limitations
- Research Methodology
- Data Mining
- Secondary Research
- Primary Research
- Subject-Matter Experts’ Advice
- Quality Checks
- Final Review
- Data Triangulation
- Bottom-Up Approach
- Top-Down Approach
- Research Flow
- Data Sources
- Data Mining
- Executive Summary
- Market Overview
- Global Cancer Diagnostics Market Outlook
- Market Drivers
- Market Restraints
- Market Opportunities
- Impact of Covid-19 On Global Cancer Diagnostics Market
- Global Cancer Diagnostics Market Outlook
- Global Cancer Diagnostics Market by Product, (USD Million)
- Consumables
- Instruments
- Global Cancer Diagnostics Market by Application, (USD Million)
- Breast Cancer
- Lung Cancer
- Blood Cancer
- Colorectal Cancer
- Skin Cancer
- Ovarian Cancer
- Prostate Cancer
- Kidney Cancer
- Liver Cancer
- Pancreatic Cancer
- Cervical Cancer
- Global Cancer Diagnostics Market by End Use, (USD Million)
- Hospitals & Clinics
- Diagnostic Laboratories
- Diagnostic Centers
- Research Institutes
- Global Cancer Diagnostics Market by Region, (USD Million)
- Introduction
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- South-East Asia
- Rest of Asia-Pacific
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Russia
- Rest of Europe
- South America
- Brazil
- Argentina
- Colombia
- Rest of South America
- Middle East and Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East and Africa
- Company Profiles* (Business Overview, Company Snapshot, Applications Offered, Recent Developments)
-
- Abbott
- Agilent Technologies, Inc.
- BD
- BioMérieux SA
- NeoGenomics Laboratories, Inc.
- Telerad Tech
- Hoffmann-La Roche Ltd
- Hologic Inc.
- Illumina, Inc.
- QIAGEN
- BioGenex
- Siemens Healthcare GmbH
- BioNTech Diagnostics GmbH
- Others *The Company List Is Indicative
-
LIST OF TABLES
TABLE 1Â Â Â Â Â Â Â Â Â GLOBAL CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 2Â Â Â Â Â Â Â Â Â GLOBAL CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 3Â Â Â Â Â Â Â Â Â GLOBAL CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 4Â Â Â Â Â Â Â Â Â GLOBAL CANCER DIAGNOSTICS MARKET BY REGION (USD MILLIONS) 2020-2029
TABLE 5Â Â Â Â Â Â Â Â Â US CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 6Â Â Â Â Â Â Â Â Â US CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 7Â Â Â Â Â Â Â Â Â US CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 8Â Â Â Â Â Â Â Â Â CANADA CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 9Â Â Â Â Â Â Â Â Â CANADA CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 10Â Â Â Â Â Â CANADA CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 11Â Â Â Â Â Â MEXICO CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 12Â Â Â Â Â Â MEXICO CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 13Â Â Â Â Â Â MEXICO CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 14Â Â Â Â Â Â BRAZIL CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 15Â Â Â Â Â Â BRAZIL CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 16Â Â Â Â Â Â BRAZIL CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 17Â Â Â Â Â Â ARGENTINA CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 18Â Â Â Â Â Â ARGENTINA CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 19Â Â Â Â Â Â ARGENTINA CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 20Â Â Â Â Â Â COLOMBIA CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 21Â Â Â Â Â Â COLOMBIA CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 22Â Â Â Â Â Â COLOMBIA CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 23Â Â Â Â Â Â REST OF SOUTH AMERICA CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 24Â Â Â Â Â Â REST OF SOUTH AMERICA CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 25Â Â Â Â Â Â REST OF SOUTH AMERICA CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 26Â Â Â Â Â Â INDIA CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 27Â Â Â Â Â Â INDIA CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 28Â Â Â Â Â Â INDIA CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 29Â Â Â Â Â Â CHINA CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 30Â Â Â Â Â Â CHINA CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 31Â Â Â Â Â Â CHINA CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 32Â Â Â Â Â Â JAPAN CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 33Â Â Â Â Â Â JAPAN CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 34Â Â Â Â Â Â JAPAN CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 35Â Â Â Â Â Â SOUTH KOREA CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 36Â Â Â Â Â Â SOUTH KOREA CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 37Â Â Â Â Â Â SOUTH KOREA CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 38Â Â Â Â Â Â AUSTRALIA CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 39Â Â Â Â Â Â AUSTRALIA CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 40Â Â Â Â Â Â AUSTRALIA CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 41Â Â Â Â Â Â SOUTH-EAST ASIA CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 42Â Â Â Â Â Â SOUTH-EAST ASIA CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 43Â Â Â Â Â Â SOUTH-EAST ASIA CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 44Â Â Â Â Â Â REST OF ASIA PACIFIC CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 45Â Â Â Â Â Â REST OF ASIA PACIFIC CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 46Â Â Â Â Â Â REST OF ASIA PACIFIC CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 47Â Â Â Â Â Â GERMANY CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 48Â Â Â Â Â Â GERMANY CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 49Â Â Â Â Â Â GERMANY CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 50Â Â Â Â Â Â UK CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 51Â Â Â Â Â Â UK CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 52Â Â Â Â Â Â UK CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 53Â Â Â Â Â Â FRANCE CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 54Â Â Â Â Â Â FRANCE CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 55Â Â Â Â Â Â FRANCE CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 56Â Â Â Â Â Â ITALY CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 57Â Â Â Â Â Â ITALY CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 58Â Â Â Â Â Â ITALY CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 59Â Â Â Â Â Â SPAIN CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 60Â Â Â Â Â Â SPAIN CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 61Â Â Â Â Â Â SPAIN CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 62Â Â Â Â Â Â RUSSIA CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 63Â Â Â Â Â Â RUSSIA CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 64Â Â Â Â Â Â RUSSIA CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 65Â Â Â Â Â Â REST OF EUROPE CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 66Â Â Â Â Â Â REST OF EUROPE CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 67Â Â Â Â Â Â REST OF EUROPE CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 68Â Â Â Â Â Â UAE CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 69Â Â Â Â Â Â UAE CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 70Â Â Â Â Â Â UAE CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 71Â Â Â Â Â Â SAUDI ARABIA CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 72Â Â Â Â Â Â SAUDI ARABIA CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 73Â Â Â Â Â Â SAUDI ARABIA CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 74Â Â Â Â Â Â SOUTH AFRICA CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 75Â Â Â Â Â Â SOUTH AFRICA CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 76Â Â Â Â Â Â SOUTH AFRICA CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
TABLE 77Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA CANCER DIAGNOSTICS MARKET BY PRODUCT (USD MILLIONS) 2020-2029
TABLE 78Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA CANCER DIAGNOSTICS MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 79Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA CANCER DIAGNOSTICS MARKET BY END USE (USD MILLIONS) 2020-2029
LIST OF FIGURES
FIGURE 1Â Â Â Â Â Â MARKET DYNAMICS
FIGURE 2Â Â Â Â Â Â MARKET SEGMENTATION
FIGURE 3Â Â Â Â Â Â REPORT TIMELINES: YEARS CONSIDERED
FIGURE 4Â Â Â Â Â Â DATA TRIANGULATION
FIGURE 5Â Â Â Â Â Â BOTTOM-UP APPROACH
FIGURE 6Â Â Â Â Â Â TOP-DOWN APPROACH
FIGURE 7Â Â Â Â Â Â RESEARCH FLOW
FIGURE 8Â Â Â Â Â Â GLOBAL CANCER DIAGNOSTICS MARKETBY PRODUCT, USD MILLION, 2020-2029
FIGURE 10Â Â Â Â GLOBAL CANCER DIAGNOSTICS MARKETBY APPLICATION, USD MILLION, 2020-2029
FIGURE 11Â Â Â Â GLOBAL CANCER DIAGNOSTICS MARKETBY END USE, USD MILLION, 2020-2029
FIGURE 12Â Â Â Â GLOBAL CANCER DIAGNOSTICS MARKETBY REGION, USD MILLION, 2020-2029
FIGURE 13    PORTER’S FIVE FORCES MODEL
FIGURE 14Â Â Â Â GLOBAL CANCER DIAGNOSTICS MARKETBY PRODUCT, 2020
FIGURE 15Â Â Â Â GLOBAL CANCER DIAGNOSTICS MARKETBY APPLICATION 2020
FIGURE 16Â Â Â Â GLOBAL CANCER DIAGNOSTICS MARKETBY END USE 2020
FIGURE 17Â Â Â Â CANCER DIAGNOSTICS MARKETBY REGION 2020
FIGURE 18Â Â Â Â MARKET SHARE ANALYSIS
FIGURE 19Â Â Â Â ABBOTT: COMPANY SNAPSHOT
FIGURE 20Â Â Â Â AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
FIGURE 21Â Â Â Â BD: COMPANY SNAPSHOT
FIGURE 22    BIOMÉRIEUX SA: COMPANY SNAPSHOT
FIGURE 23Â Â Â Â NEOGENOMICS LABORATORIES, INC.: COMPANY SNAPSHOT
FIGURE 24Â Â Â Â TELERAD TECH: COMPANY SNAPSHOT
FIGURE 25Â Â Â Â F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
FIGURE 26Â Â Â Â HOLOGIC INC.: COMPANY SNAPSHOT
FIGURE 27Â Â Â Â ILLUMINA, INC.: COMPANY SNAPSHOT
FIGURE 28Â Â Â Â QIAGEN: COMPANY SNAPSHOT
FIGURE 29Â Â Â Â BIOGENEX: COMPANY SNAPSHOT
FAQ
The cancer diagnostics market size was valued at USD 16.87 billion in 2020 and is projected to reach USD 44.22 billion by 2029, growing at a CAGR of 11.3% from 2022 to 2029 due to an increase in the incidence and prevalence of various types of cancer.
North America held more than 40% of the cancer diagnostics market revenue share in 2021. Technological breakthroughs in diagnostic tests, rising healthcare spending, and more patient knowledge about early cancer diagnosis are some of the major reasons driving diagnostics adoption in the region.
Cancer research organizations, as well as public and commercial entities, are substantially investing in research initiatives in order to bring better diagnostic tools to market that can diagnose the disease long before symptoms occur.
The global cancer diagnostics market registered a CAGR of 11.3% from 2022 to 2029. The consumables segment is the major revenue contributor in the market.
The breast cancer segment is the largest application in the cancer diagnostics market.
North America is the largest market for cancer diagnostics market.
In-Depth Database
Our Report’s database covers almost all topics of all regions over the Globe.
Recognised Publishing Sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales
support.
Safe & Secure
Complete secure payment
process.